Pharmaceutical companies approach ‘Pay for Performance’ programs, and One has to ask Why? The obvious Answer states that the Drug companies are failing to receive the Volume sales for their Drugs which would justify the Research Costs. A major factor must be Insurer resistence to qualifying new Drugs for line payment. The chief impulse behind this can only be the wide range of cheaper Drugs already on the Market to treat the same ailments. The Secondary condition consists of that existent Patient group who must share the Payment load, and are refusing to make the huge jump.
Pay for Performance will degenerate into a sad Joke, as Standards will quickly decline to where Placebo treatments will likely work as well. Insurers should not engage in such Marketing schemes unless Pharmaceutical companies provide Comparison Tests utilizing Equivalent drugs with Patent expired. Here alone will be a Testing system in which Cost performance can be evaluated.
Drugs companies have long become unionized Job Protection organizations for Research personnel; within an industry lavishly funded by indifferent Payer systems. Much of this Research Funding could be better spent, at least from the Patient and Insurer prospective, in superior medical facilities at cheaper Cost. I still am an advocate of specific-royalty Patents issued on the evaluated Need for the Drug; one way to contain the overflowing Research budgets. lgl
No comments:
Post a Comment